Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Roche Diagnostics,...

Roche Diagnostics, Redcliffe Labs collaborate for early Alzheimer's prediction

Ruchika SharmaWritten by Ruchika Sharma Published On 2022-11-04T11:21:39+05:30  |  Updated On 4 Nov 2022 5:52 AM GMT
Roche Diagnostics, Redcliffe Labs collaborate for early Alzheimers prediction

New Delhi: Redcliffe Labs has partnered with Roche Diagnostics India to offer a combination of Roche Diagnostics' biomarker testing with Redcliffe Labs genetic testing for early Alzheimer's prediction.Through the collaboration, Redcliffe Labs will be the first to bring to India Roche Diagnostics' Elecsys ß-Amyloid (1-42) CSF II (cerebrospinal fluid), Elecsys Phospho-Tau (181P) CSF and...

New Delhi: Redcliffe Labs has partnered with Roche Diagnostics India to offer a combination of Roche Diagnostics' biomarker testing with Redcliffe Labs genetic testing for early Alzheimer's prediction.

Through the collaboration, Redcliffe Labs will be the first to bring to India Roche Diagnostics' Elecsys ß-Amyloid (1-42) CSF II (cerebrospinal fluid), Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF immunoassays. Elecsys AD CSF tests are intended for use in adult patients with cognitive impairment to aid in the early diagnosis of Alzheimer's disease (AD) and to identify patients with mild cognitive impairment (MCI) who are at increased risk of cognitive decline.

Elecsys AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence. These in-vitro diagnostic immunoassays are for the measurement of ß-Amyloid (1–42), phospho-Tau, and total Tau protein concentrations in CSF of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of dementia.

Mr. Dheeraj Jain, the Founder & Managing Director of Redcliffe Labs said "Alzheimer's has a significant adverse impact on public health, including incidence, mortality, morbidity, and associated costs of care. More than 5 million people in India alone suffer from dementia, with AD thought to account for 60% to 80% of cases. Currently, a considerable portion of AD diagnoses are made mainly on clinical symptoms, including cognitive tests, and many people are identified after their illness is extremely advanced. 50% to 75% of those who have dementia do not have an official MCI or AD diagnosis. Furthermore, 70 to 80 percent of AD diagnoses are correct when based solely on cognitive tests. This partnership between Redcliffe Labs and Roche Diagnostics will mark a significant turning point as, with the help of CSF immunoassays, the accuracy of an AD diagnosis is increased and the development of the disease can be assessed by doctors."

Mr. Narendra Varde, Managing Director, Roche Diagnostics India and Neighboring Markets said, "India currently faces a dual problem in terms of lack of effective diagnostic mechanisms and access to treatment for dementia and Alzheimer's disease. According to a 2020 report by the Alzheimer's and Related Disorders Society of India (ARDSI), an estimated 5.3 million people above the age of 60 have dementia in the country, and the burden of Alzheimer's is expected to increase in the coming years. The need of the hour is to ensure timely diagnosis and intervention. To bridge this need gap, I am excited to introduce the Elecsys CSF tests, which offers a standardised pre-analytical protocol for clinicians and labs to provide reliable, safe, and accurate identification of patients with Alzheimer's disease."

Ishaan Khanna, Director of Reproductive Medicine and Genetics, Redcliffe Labs, said "The availability of an Elecsys AD CSF test can potentially eliminate the need for time-consuming and expensive scans, which is great news for individuals and families concerned with the possibility of an Alzheimer's disease diagnosis. With the Elecsys AD CSF test, there is a new option that can typically be completed on the same day and can give doctors the same information regarding brain amyloid status without the radiation risk, to help determine if a patient's cognitive impairment is due to Alzheimer's disease."

Read also: Matt Sause to become new CEO of Roche Diagnostics
Redcliffe Labs Redcliffe Labs news Roche Diagnostics India Roche Diagnostics Alzheimer's disease 
Ruchika Sharma
Ruchika Sharma

    M.Com

    Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article

    More News

    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X